Levin Comments on Trump Administration’s Toothless Plan to Tackle Prescription Drug Costs

May 11, 2018 Issues: Health Care

WASHINGTON, D.C. - Representative Sandy Levin (D-MI), Ranking Member on the House Ways and Means Subcommittee on Health, issued the following statement in response to today’s announcement by the Trump Administration regarding prescription drug costs:

“President Trump has repeatedly promised to reduce the high cost of prescription medicines, but the American people have yet to see any real action a year and a half into his Administration. Today’s announcement was filled with more promises, but it fails to spell out viable reforms needed to really move the needle on cutting prescription drug prices.

“His announcement rejects two of his own campaign promises: (1) using the Medicare program’s enormous leverage to directly negotiate lower drug prices for senior citizens; and (2) allowing the safe re-importation of cheaper medicines from Canada. Further, there is no meaningful proposal for holding drug companies accountable for excessive price increases, even after President Trump said they were ‘getting away with murder’.

“The President has taken notice that patients in most countries pay less for medicine than here in the United States. Calling on those in other countries to pay more for their medicine will not assure in any way that patients in America pay less.”

This past March, Rep. Levin introduced legislation to strengthen Medicare and reduce drug costs for patients. The bill would require prescription drug companies to pay a rebate when the price of their Part B drug increases faster than inflation.